A director at Kingsway Financial Services Inc sold 44,698 shares at 12.800USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Synaptics Showcases Edge AI Innovations at CES 2026 Featuring Synaptics Astra™, Veros™, and Multimodal Sensing SAN JOSE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced that it will showcase a broad portfolio of AI-native processing, sensing, and connectivity technologies at CES 2026. These solutions demonstrate how intelligence at the Edge transforms real-world applications across consumer, industrial, smart home, and enterprise markets.As global demand grows for devices that can interpret their environment, make context-aware decisions, and...
A director at Synaptics Inc sold 18,285 shares at 80.291USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Lesaka Webcast and Conference Call to Review Second Quarter 2026 Results JOHANNESBURG, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ: LSAK, JSE: LSK) ("Lesaka") today announced it will release second quarter 2026 results after the U.S. market close on February 4, 2026. Lesaka management will host a presentation webcast and conference call on February 5, 2026, at 8:00am EDT (3:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: Participants using the webcast will be able to...
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated First ex-U.S. SLE patient treated with FT819 expands enrollment capacity and supports unique ability of FT819 for broad, on-demand patient accessibility Preclinical stu...
Synaptics to Participate at Upcoming Investor Conferences on Tuesday, December 2, 2025 and Wednesday, December 10, 2025 SAN JOSE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced its participation in upcoming investor conferences. Rahul Patel, President and Chief Executive Officer, will participate in UBS’ Global Technology and AI Conference 2025 on Tuesday, December 2, 2025Rahul Patel, President and Chief Executive Officer, and Ken Rizvi, CFO, will present at Barclays 23rd Annual Global Technology Conference on Wednesday, December 10, 2025 at ...
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 in New York, New York. Company management will p...
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as indu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.